HTA56 ICER Vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT)
Abstract
Authors
Y Bappoo J Ader K Freemyer W Wright